Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.
Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.
Some of our industry partners. We are delighted to have established partnerships with prominent pharmaceutical companies that have adopted our Dispersome® Technology. These valued collaborations underscore our commitment to advancing drug solubility, positively impacting patient well-being, and shaping the future of drug delivery.
Our proprietary Dispersome® technology is grounded in over a decade of research and continuously validated through peer-reviewed studies in leading pharmaceutical journals.
These publications showcase our breakthroughs in enhancing drug solubility and bioavailability for small molecule drugs.
